JP2001520042A5 - - Google Patents

Download PDF

Info

Publication number
JP2001520042A5
JP2001520042A5 JP2000517087A JP2000517087A JP2001520042A5 JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5 JP 2000517087 A JP2000517087 A JP 2000517087A JP 2000517087 A JP2000517087 A JP 2000517087A JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
vitamin
gla domain
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000517087A
Other languages
English (en)
Japanese (ja)
Other versions
JP4276379B2 (ja
JP2001520042A (ja
Filing date
Publication date
Priority claimed from US08/955,636 external-priority patent/US6017882A/en
Application filed filed Critical
Publication of JP2001520042A publication Critical patent/JP2001520042A/ja
Publication of JP2001520042A5 publication Critical patent/JP2001520042A5/ja
Application granted granted Critical
Publication of JP4276379B2 publication Critical patent/JP4276379B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000517087A 1997-10-23 1998-10-20 改変型ビタミンk依存性ポリペプチド Expired - Fee Related JP4276379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides
US08/955,636 1997-10-23
PCT/US1998/022152 WO1999020767A1 (en) 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides

Publications (3)

Publication Number Publication Date
JP2001520042A JP2001520042A (ja) 2001-10-30
JP2001520042A5 true JP2001520042A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4276379B2 JP4276379B2 (ja) 2009-06-10

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000517087A Expired - Fee Related JP4276379B2 (ja) 1997-10-23 1998-10-20 改変型ビタミンk依存性ポリペプチド

Country Status (30)

Country Link
US (1) US6017882A (cg-RX-API-DMAC7.html)
EP (2) EP1090128B1 (cg-RX-API-DMAC7.html)
JP (1) JP4276379B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010031370A (cg-RX-API-DMAC7.html)
CN (1) CN1246462C (cg-RX-API-DMAC7.html)
AP (1) AP2000001811A0 (cg-RX-API-DMAC7.html)
AR (2) AR020048A1 (cg-RX-API-DMAC7.html)
AT (1) ATE390486T1 (cg-RX-API-DMAC7.html)
AU (1) AU749279C (cg-RX-API-DMAC7.html)
BR (1) BR9814611A (cg-RX-API-DMAC7.html)
CA (1) CA2307175C (cg-RX-API-DMAC7.html)
DE (1) DE69839313T2 (cg-RX-API-DMAC7.html)
DK (1) DK1090128T3 (cg-RX-API-DMAC7.html)
EA (1) EA200000449A1 (cg-RX-API-DMAC7.html)
ES (2) ES2303362T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20000234A2 (cg-RX-API-DMAC7.html)
HU (1) HU225993B1 (cg-RX-API-DMAC7.html)
ID (1) ID26330A (cg-RX-API-DMAC7.html)
IL (1) IL135603A0 (cg-RX-API-DMAC7.html)
IS (1) IS5449A (cg-RX-API-DMAC7.html)
MY (1) MY136336A (cg-RX-API-DMAC7.html)
NO (1) NO20002025L (cg-RX-API-DMAC7.html)
NZ (1) NZ504114A (cg-RX-API-DMAC7.html)
PL (1) PL194194B1 (cg-RX-API-DMAC7.html)
PT (1) PT1090128E (cg-RX-API-DMAC7.html)
SG (1) SG105547A1 (cg-RX-API-DMAC7.html)
TR (1) TR200001105T2 (cg-RX-API-DMAC7.html)
TW (1) TW587081B (cg-RX-API-DMAC7.html)
WO (1) WO1999020767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA989597B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
AU2001232736A1 (en) 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU2001278336B2 (en) * 2000-07-31 2007-01-18 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002235073B2 (en) * 2001-03-02 2007-02-01 T.A.C. Thrombosis And Coagulation Ab Protein C variants
WO2003073980A2 (en) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c variants
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
EP3103869A1 (en) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第VII因子または第VIIa因子のGlaドメイン変種
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第vii因子ポリペプチド
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子vii多肽和其用途
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
CN102686603B (zh) * 2009-12-14 2014-12-17 国立大学法人北海道大学 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインc及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Similar Documents

Publication Publication Date Title
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
Sadler Thrombomodulin structure and function
Kato et al. Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme
TW585871B (en) Improved methods for processing activated protein C
Clark et al. Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phosoholipase C in mammalian cells
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2400295A1 (en) Modified factor viii
US6465624B1 (en) Purification of von-Willebrand factor by cation exchanger chromatography
US8022187B2 (en) FVIII-independent FIX-mutant proteins for hemophilia A treatment
CA2102208A1 (en) Binding domains in notch and delta proteins
JP2002513556A5 (cg-RX-API-DMAC7.html)
KR20160008521A (ko) 콜레스테롤 수준을 변경하는 조성물 및 방법
AU2008209985A1 (en) Improved fix-mutant proteins for hemophilia B treatment
KR910003094A (ko) 흡혈박쥐속(Vampire bat) 타액 플라스미노겐 활성인자
CA2563675A1 (en) Recombinantly modified plasmin
Orawski et al. Purification and properties of membrane-bound aminopeptidase P from rat lung
AU2444795A (en) A process for separating milk clotting enzymes, and stable rennet compositions
Friedman et al. Vitamin K-dependent carboxylation
JP7843331B2 (ja) 第xa因子及び誘導体を調製するための組成物及び方法
CA1258242A (en) Urokinase zymogen and composition containing the same
Noda et al. Activation of immobilized, biotinylated choleragen A1 protein by a 19-kilodalton guanine nucleotide-binding protein
Vatandoost et al. Effect of propeptide amino acid substitution in γ‐carboxylation, activity and expression of recombinant human coagulation factor IX
ATE121456T1 (de) Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus.
JPH05506354A (ja) 端が切り取られた軽鎖を有する活性プロテインc
Fischer et al. Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells